BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024 16:05 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
August 06, 2024 16:05 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
July 23, 2024 07:10 ET
|
BioRestorative Therapies, Inc
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
June 27, 2024 07:40 ET
|
BioRestorative Therapies, Inc
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem® licensing opportunities – –...
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
June 17, 2024 07:05 ET
|
BioRestorative Therapies, Inc
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
June 13, 2024 07:00 ET
|
BioRestorative Therapies, Inc
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders – - ThermoStem® is an off-the-shelf...
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
June 04, 2024 08:50 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
May 24, 2024 19:45 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies Provides First Quarter 2024 Business Update
May 14, 2024 16:10 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
May 08, 2024 07:30 ET
|
BioRestorative Therapies, Inc
— New therapeutic candidate developed using Company’s patented ThermoStem® platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and...